Sameem Abedin, MD

Assistant Professor

view physician profile

Locations

Froedtert Hospital
Cancer Center - Froedtert Hospital

Specialties

Hematology
Medical Oncology

Languages

English, Bengali

Cancer Center - Froedtert Hospital

(414) 805-0505

Education

MD - Doctor of Medicine

Biography

Sameem Abedin, MD, is an Assistant Professor of Medicine at the Medical College of Wisconsin, Division of Hematology and Oncology. His specialization is in leukemia and stem cell transplantation at Froedtert Hospital. He obtained his undergraduate degree at the University of Pennsylvania, PA, in 2004, and his medical degree at Jefferson Medical College in 2009. He completed his residency in Internal Medicine at the University of Pittsburgh Medical Center in Pittsburgh, PA, in 2012. In 2017, he then completed his fellowship in Hematology and Oncology at Northwestern University in Chicago, IL, where he also served as Chief Fellow. His current clinical and research interests include patients with acute leukemia, including AML and ALL, myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPNs), chronic myeloid leukemia (CML), and allogeneic stem cell transplantation for these conditions. His professional memberships include the American Society of Hematology and the American Society of Bone Marrow Transplantation.

Dr. Abedin is board certified by the American Board of Internal Medicine (ABIM) in Internal Medicine, and in Hematology and Medical Oncology.

Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR-T cell therapy.

(Dhakal B, Abedin SM, Fenske TS, Chhabra S, Ledeboer N, Hari P, Hamadani M.) Blood. 2021 Aug 02 PMID: 34339501 PMCID: PMC8332674 08/03/2021
Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease - a real-world outcomes analysis.

(Abedin S, Rashid N, Schroeder M, Romee R, Nauffal M, Alhaj Moustafa M, Kharfan-Dabaja MA, Palmer J, Hogan W, Hefazi M, Larson S, Holtan S, DeFilipp Z, Jayani R, Dholaria B, Pidala J, Khimani F, Grunwald MR, Butler C, Hamadani M.) Br J Haematol. 2021 Jul 12 PMID: 34254289 07/14/2021
Bronchoalveolar lavage-based COVID-19 testing in patients with cancer.

(Abid MB, Chhabra S, Buchan B, Graham MB, Abedin S, Thapa B, D'Souza A, George B, Hamadani M.) Hematol Oncol Stem Cell Ther. 2021 Mar;14(1):65-70 PMID: 33058787 PMCID: PMC7543702 SCOPUS ID: 2-s2.0-85092735525 10/16/2020
Corrigendum to ‘Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation’ [Biology of Blood and Marrow Transplantation 26/10 (2020) 1876-1885] (Biology of Blood and Marrow Transplantation (2020) 26/10(1876-1885) (S1083879120304146), (10.1016/j.bbmt.2020.07.005))

(Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Rizzo JD, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M.) Transplantation and Cellular Therapy. 2021 SCOPUS ID: 2-s2.0-85101258094 01/01/2021
Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia.

(Mushtaq MU, Harrington AM, Chaudhary SG, Michaelis LC, Carlson KB, Abedin S, Runass L, Callander NS, Fallon MJ, Juckett M, Hall AC, Hematti P, Mattison RJ, Atallah EL, Guru Murthy GS.) Leuk Lymphoma. 2021 01;62(1):158-166 PMID: 32951486 SCOPUS ID: 2-s2.0-85091139710 09/22/2020
Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation.

(Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Douglas Rizzo J, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M.) Biol Blood Marrow Transplant. 2020 10;26(10):1876-1885 PMID: 32653622 PMCID: PMC7571859 SCOPUS ID: 2-s2.0-85089134303 07/13/2020
Letter to the Editor Regarding Diagnostic Considerations for COVID-19 in Recipients of Allogeneic Hematopoietic Cell Transplantation.

(Chhabra S, Abedin S, Graham MB, Ferrer Marrero TM, Hari PN, Shaw BE.) Biol Blood Marrow Transplant. 2020 09;26(9):e241-e242 PMID: 32589922 PMCID: PMC7309826 SCOPUS ID: 2-s2.0-85087728830 06/27/2020
Severity of Cytokine Release Syndrome and Its Association with Infections after T Cell-Replete Haploidentical Related Donor Transplantation.

(Abid MB, Hamadani M, Szabo A, Hari PN, Graham MB, Frank MO, Collier WS, Abedin S, Jerkins JH, Pasquini MC, Runaas L, Shah NN, Chhabra S.) Biol Blood Marrow Transplant. 2020 09;26(9):1670-1678 PMID: 32562858 SCOPUS ID: 2-s2.0-85087739042 06/21/2020
Reducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginase-A real world study.

(George G, Rezazadeh A, Zook F, Pearl N, McCoy C, Carlson K, Runaas L, Abedin S, Guru Murthy GS, Michaelis LC, Atallah E, Baumann-Kreuziger L.) Leuk Res. 2020 07;94:106368 PMID: 32442786 SCOPUS ID: 2-s2.0-85084755644 05/23/2020
Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease.

(Abedin SM, Hamadani M.) Expert Opin Investig Drugs. 2020 May;29(5):423-427 PMID: 32293938 SCOPUS ID: 2-s2.0-85083651597 04/16/2020
Experimental Pharmaceuticals for Steroid-Refractory Acute Graft-versus-Host Disease.

(Abedin S, Hamadani M.) J Exp Pharmacol. 2020;12:549-557 PMID: 33273867 PMCID: PMC7705269 12/05/2020
Reducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginase—A real world study

(George G, Rezazadeh A, Zook F, Pearl N, McCoy C, Carlson K, Runaas L, Abedin S, Guru Murthy GS, Michaelis LC, Atallah E, Baumann-Kreuziger L.) Leukemia Research. July 2020;94 SCOPUS ID: 2-s2.0-85084755644 07/01/2020